Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pelabresib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2022-02-01

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.

Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Hayashizaki Y, Carter BZ, Tabe Y, Andreeff M.

Transl Oncol · research-article; journal article · DOI 10.1016/j.tranon.2022.101354

Bibliografisk träff 2021-04-27

Next Generation Therapeutics for the Treatment of Myelofibrosis.

Tremblay D, Mascarenhas J.

Cells · review-article; review; journal article · DOI 10.3390/cells10051034

Bibliografisk träff 2021-01-28

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma.

Shigeta S, Lui GYL, Shaw R, Moser R, Gurley KE, Durenberger G, Rosati R, Diaz RL, Ince TA, Swisher EM, Grandori C, Kemp CJ.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-20-0809

Bibliografisk träff 2021-01-26

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials.

Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z.

Front Pharmacol · review-article; review; journal article · DOI 10.3389/fphar.2020.621093

Bibliografisk träff 2020-09-11

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.

Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.

EBioMedicine · research-article; journal article · DOI 10.1016/j.ebiom.2020.102988

Bibliografisk träff 2020-04-29

Investigational non-JAK inhibitors for chronic phase myelofibrosis.

Bankar A, Gupta V.

Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2020.1751121

Bibliografisk träff 2019-11-01

The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis.

Raythatha J, Arnold L.

Epigenomics · journal article · DOI 10.2217/epi-2019-0274

Bibliografisk träff 2018-12-04

Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.

Zhao L, Okhovat JP, Hong EK, Kim YH, Wood GS.

Neoplasia · research-article; journal article · DOI 10.1016/j.neo.2018.11.006

Bibliografisk träff 2016-11-28

Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.

Siu KT, Ramachandran J, Yee AJ, Eda H, Santo L, Panaroni C, Mertz JA, Sims Iii RJ, Cooper MR, Raje N.

Leukemia · journal article · DOI 10.1038/leu.2016.355

Bibliografisk träff 2016-02-04

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.

Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Côté A, Leblanc Y, Nasveschuk CG, Bellon S, Bergeron L, Campbell R, Cantone N, Cooper MR, Cummings RT, Jayaram H, Joshi S, Mertz JA, Neiss A, Normant E, O'Meara M, Pardo E, Poy F, Sandy P, Supko J, Sims RJ, Harmange JC, Taylor AM, Audia JE.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.5b01882